Search

Your search keyword '"Fiorentino, Michelangelo"' showing total 674 results
Start Over Author "Fiorentino, Michelangelo" Publication Type Academic Journals
674 results on '"Fiorentino, Michelangelo"'

2. Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals.

Author

Iyer, Hari, Vaselkiv, Jane, Stopsack, Konrad, Roscoe, Charlotte, DeVille, Nicole, Zhang, Yiwen, Penney, Kathryn, Balk, Steven, Fiorentino, Michelangelo, Hart, Jaime, De Vivo, Immaculata, Mucci, Lorelei, Laden, Francine, Rebbeck, Timothy, and James, Peter

Subjects
atrophy, inflammation, neighborhood, prostate cancer, prostatic neoplasms, residence characteristics, socioeconomic factors, Humans, Male, Environment, Follow-Up Studies, Inflammation, Prostatic Neoplasms, Residence Characteristics, Social Class, Socioeconomic Factors
Abstract

Adverse neighborhood social and natural (green space) environments may contribute to the etiology of prostate cancer (CaP), but mechanisms are unclear. We examined associations between neighborhood environment and prostate intratumoral inflammation in 967 men diagnosed with CaP with available tissue samples from 1986-2009 in the Health Professionals Follow-up Study. Exposures were linked to work or residential addresses in 1988. We estimated indices of neighborhood socioeconomic status (nSES) and segregation (Index of Concentration at the Extremes (ICE)) using US Census tract-level data. Surrounding greenness was estimated using seasonal averaged Normalized Difference Vegetation Index (NDVI) data. Surgical tissue underwent pathological review for acute and chronic inflammation, corpora amylacea, and focal atrophic lesions. Adjusted odds ratios (aORs) for inflammation (ordinal) and focal atrophy (binary) were estimated using logistic regression. No associations were observed for acute or chronic inflammation. Each interquartile-range increase in NDVI within 1,230 m of the participants work or home address (aOR = 0.74, 95% confidence interval (CI): 0.59, 0.93), in ICE-income (aOR = 0.79, 95% CI: 0.61, 1.04), and in ICE-race/income (aOR = 0.79, 95% CI: 0.63, 0.99) was associated with lower odds of postatrophic hyperplasia. Interquartile-range increases in nSES (aOR = 0.76, 95% CI: 0.57, 1.02) and ICE-race/income (aOR = 0.73, 95% CI: 0.54, 0.99) were associated with lower odds of tumor corpora amylacea. Histopathological inflammatory features of prostate tumors may be influenced by neighborhood.

Published
2023

3. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.

Author

Stopsack, Konrad H, Su, Xiaofeng A, Vaselkiv, J Bailey, Graff, Rebecca E, Ebot, Ericka M, Pettersson, Andreas, Lis, Rosina T, Fiorentino, Michelangelo, Loda, Massimo, Penney, Kathryn L, Lotan, Tamara L, and Mucci, Lorelei A

Subjects
Clinical Research, Genetics, Prostate Cancer, Human Genome, Urologic Diseases, Cancer, Aetiology, 2.1 Biological and endogenous factors, Male, Humans, Transcriptome, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-ets, Prostatic Neoplasms, Gene Expression Profiling, Transcriptional Regulator ERG, Serine Endopeptidases, Oncology and Carcinogenesis, Developmental Biology, Oncology & Carcinogenesis
Abstract

The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology. A smaller subset of other tumors harbor fusions between TMPRSS2 and members of the ETS transcription factor family other than ERG. To assess the genomic similarity of tumors with non-ERG ETS fusions and those with fusions involving ERG, this study derived a transcriptomic signature of non-ERG ETS fusions and assessed this signature and ERG-related gene expression in 1,050 men with primary prostate cancer from three independent population-based and hospital-based studies. Although non-ERG ETS fusions involving ETV1, ETV4, ETV5, or FLI1 were individually rare, they jointly accounted for one in seven prostate tumors. Genes differentially regulated between non-ERG ETS tumors and tumors without ETS fusions showed similar differential expression when ERG tumors and tumors without ETS fusions were compared (differences explained: R2 = 69-77%), including ETS-related androgen receptor (AR) target genes. Differences appeared to result from similarities among ETS tumors rather than similarities among non-ETS tumors. Gene sets associated with ERG fusions were consistent with gene sets associated with non-ERG ETS fusions, including fatty acid and amino acid metabolism, an observation that was robust across cohorts.ImplicationsConsidering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely similar fashion, most notably genes regulating metabolic pathways.

Published
2023

4. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT

Author

Ricci, Costantino, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Grillini, Alessia, Franchini, Eugenia, Grillini, Marco, Schiavina, Riccardo, Massari, Francesco, Mollica, Veronica, Tateo, Valentina, Bianchi, Federico Mineo, Bianchi, Lorenzo, Droghetti, Matteo, Maloberti, Thais, Tallini, Giovanni, Colecchia, Maurizio, Acosta, Andres Martin, Lobo, João, Trpkov, Kiril, Fiorentino, Michelangelo, and de Biase, Dario

Published
2023
Full Text
View/download PDF

5. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer.

Author

Noronha, Ashish, Belugali Nataraj, Nishanth, Sang Lee, Joo, Zhitomirsky, Benny, Oren, Yaara, Oster, Sara, Lindzen, Moshit, Mukherjee, Saptaparna, Will, Rainer, Ghosh, Soma, Simoni-Nieves, Arturo, Verma, Aakanksha, Chatterjee, Rishita, Borgoni, Simone, Robinson, Welles, Sinha, Sanju, Brandis, Alexander, Kerr, D Lucas, Wu, Wei, Sekar, Arunachalam, Giri, Suvendu, Chung, Youngmin, Drago-Garcia, Diana, Danysh, Brian P, Lauriola, Mattia, Fiorentino, Michelangelo, Ardizzoni, Andrea, Oren, Moshe, Blakely, Collin M, Ezike, Jideofor, Wiemann, Stefan, Parida, Laxmi, Bivona, Trever G, Aqeilan, Rami I, Brugge, Joan S, Regev, Aviv, Getz, Gad, Ruppin, Eytan, and Yarden, Yosef

Abstract

Anti-cancer therapies have been limited by emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells and in EGFRi-treated patients presenting residual disease we observed upregulation of GAS6, while ablation of GAS6's receptor, AXL, eradicated resistance. Reciprocally, AXL overexpression enhanced DTP survival and accelerated the emergence of T790M, an EGFR mutation typical to resistant cells. Mechanistically, AXL induces low-fidelity DNA polymerases and activates their organizer, RAD18, by promoting neddylation. Metabolomics uncovered another hypermutator, AXL-driven activation of MYC and increased purine synthesis that is unbalanced by pyrimidines. Aligning anti-AXL combination treatments with the transition from DTPs to resistant cells cured patient-derived xenografts. Hence, similar to bacteria, tumors tolerate therapy by engaging pharmacologically targetable endogenous mutators.

Published
2022

9. Site-specific concordance of targeted and systematic biopsy cores at the index lesion on multiparametric magnetic resonance: can we spare the double-tap?

Author

Droghetti, Matteo, Bianchi, Lorenzo, Beretta, Carlo, Balestrazzi, Eleonora, Costa, Francesco, Feruzzi, Alberto, Piazza, Pietro, Roveroni, Carlo, Gaudiano, Caterina, Corcioni, Beniamino, Giunchi, Francesca, Fiorentino, Michelangelo, Golfieri, Rita, Schiavina, Riccardo, and Brunocilla, Eugenio

Published
2023
Full Text
View/download PDF

11. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis

Author

Melotti, Sofia, Ambrosi, Francesca, Franceschini, Tania, Giunchi, Francesca, Filippo, Giorgia Di, Franchini, Eugenia, Massari, Francesco, Mollica, Veronica, Tateo, Valentina, Bianchi, Federico Mineo, Colecchia, Maurizio, Acosta, Andres Martin, Lobo, João, Fiorentino, Michelangelo, and Ricci, Costantino

Published
2023
Full Text
View/download PDF

15. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease

Author

Ahearn, Thomas U, Peisch, Sam, Pettersson, Andreas, Ebot, Ericka M, Zhou, Cindy Ke, Graff, Rebecca E, Sinnott, Jennifer A, Fazli, Ladan, Judson, Gregory L, Bismar, Tarek A, Rider, Jennifer R, Gerke, Travis, Chan, June M, Fiorentino, Michelangelo, Flavin, Richard, Sesso, Howard D, Finn, Stephen, Giovannucci, Edward L, Gleave, Martin, Loda, Massimo, Li, Zhe, Pollak, Michael, and Mucci, Lorelei A

Subjects
Clinical Research, Aging, Prostate Cancer, Diabetes, Urologic Diseases, Cancer, 2.1 Biological and endogenous factors, Aetiology, Aged, Apoptosis, Biomarkers, Tumor, Cell Proliferation, Disease Progression, Gene Expression Regulation, Neoplastic, Humans, Insulin, Insulin-Like Growth Factor I, Male, Oncogene Proteins, Fusion, Prostatic Neoplasms, Receptor, IGF Type 1, Receptor, Insulin, Receptors, Somatomedin, Signal Transduction, Transcriptional Regulator ERG, Transdisciplinary Prostate Cancer Partnership, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Circulating insulin-like growth factor-1 (IGF-1) is consistently associated with prostate cancer risk. IGF-1 binds to IGF-1 receptor (IGF1R) and insulin receptor (IR), activating cancer hallmark pathways. Experimental evidence suggests that TMPRSS2:ERG may interact with IGF/insulin signaling to influence progression. We investigated IGF1R and IR expression and its association with lethal prostate cancer among 769 men. Protein expression of IGF1R, IR and ERG (i.e. a surrogate of ERG fusion genes) were assayed by immunohistochemistry. Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI) adjusted for clinical characteristics. Among patients, 29% had strong tumor IGF1R expression and 10% had strong IR expression. During a mean follow-up of 13.2 years through 2012, 80 men (11%) developed lethal disease. Tumors with strong IGF1R or IR expression showed increased cell proliferation, decreased apoptosis and a higher prevalence of ERG. In multivariable models, strong IGF1R was associated with a borderline increased risk of lethal prostate cancer (HR 1.7; 95% CI 0.9-3.1). The association appeared greater in ERG-positive tumors (HR 2.8; 95% CI 0.9-8.4) than in ERG-negative tumors (HR 1.3; 95% CI 0.6-3.0, p-heterogeneity 0.08). There was no association between IR and lethal prostate cancer (HR 0.8; 95% CI 0.4-1.9). These results suggest that tumor IGF1R expression may play a role in prostate cancer progression to a lethal phenotype and that ERG-positive tumors may be more sensitive to IGF signaling. These data may improve our understanding of IGF signaling in prostate cancer and suggest therapeutic options for disease subtypes.

Published
2018

19. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer

Author

Ciliberto, Gennaro, Canfora, Marco, Terrenato, Irene, Agnoletto, Chiara, Agustoni, Francesco, Amoroso, Loredana, Baldassarre, Gustavo, Curigliano, Giuseppe, Delmonte, Angelo, De Luca, Antonella, Fiorentino, Michelangelo, Gregorc, Vanesa, Ibrahim, Toni, Lazzari, Chiara, Mastronuzzi, Angela, Pronzato, Paolo, Santoro, Armando, Scambia, Giovanni, Tommasi, Stefania, Vingiani, Andrea, Giacomini, Patrizio, and De Maria, Ruggero

Published
2022
Full Text
View/download PDF

20. The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer

Author

Mazzeschi, Martina, Sgarzi, Michela, Romaniello, Donatella, Gelfo, Valerio, Cavallo, Carola, Ambrosi, Francesca, Morselli, Alessandra, Miano, Carmen, Laprovitera, Noemi, Girone, Cinzia, Ferracin, Manuela, Santi, Spartaco, Rihawi, Karim, Ardizzoni, Andrea, Fiorentino, Michelangelo, D’Uva, Gabriele, Győrffy, Balázs, Palmer, Ruth, and Lauriola, Mattia

Published
2022
Full Text
View/download PDF

21. Antitissue transglutaminase antibodies’ normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience

Author

Sbravati, Francesca, Cosentino, Anita, Lenzi, Jacopo, Fiorentino, Michelangelo, Ambrosi, Francesca, Salerno, Angela, Di Biase, Annarita, Righi, Beatrice, Brusa, Sandra, Valin, Paola Sogno, Bruni, Laura, Battistini, Barbara, Pagano, Sara, Grondona, Ana Gabriela, Labriola, Flavio, and Alvisi, Patrizia

Published
2022
Full Text
View/download PDF

23. β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis.

Author

Kitagawa, Yukiko, De Biase, Dario, Ricci, Costantino, Cornejo, Kristine M, Fiorentino, Michelangelo, Collins, Katrina, Idrees, Muhammad T, Colecchia, Maurizio, Ulbright, Thomas M, and Acosta, Andres Martin

Subjects
LEYDIG cells, IMMUNOHISTOCHEMISTRY, TESTIS tumors, CATENINS, SERTOLI cells, TERATOCARCINOMA, GENOMICS
Abstract

Background: Testicular Leydig cell tumours (LCTs) are the most common type of sex cord–stromal tumour in men, representing 1%–3% of all testicular neoplasms. Among testicular sex cord–stromal tumours, CTNNB1 mutations and nuclear expression of β‐catenin have been typically associated with Sertoli cell tumour. Recent genomic analyses have shown that CTNNB1 variants are also identified in a subset of LCTs; however, the frequency and clinicopathologic associations of β‐catenin alterations remain incompletely understood in this tumour type. Methods: In this study, we evaluated 32 LCTs (five malignant/metastasizing, 27 nonmetastasizing) using β‐catenin immunohistochemistry and DNA sequencing. Results: Immunohistochemistry revealed focal or multifocal nuclear β‐catenin expression in 47% of the tumours. Diffuse nuclear β‐catenin expression (in >50% of the tumour cells) was not detected in any of the cases analysed herein. Comparison of β‐catenin‐positive and β‐catenin‐negative cases did not show significant differences in the frequency of adverse histopathologic findings or malignant clinical behaviour. DNA sequencing performed de novo on a subset of seven cases revealed the presence of exon 3 CTNNB1 variants in four of them (4/7, 57%), with variant allele frequencies (VAF) ranging from 7 to 33%. Two additional β‐catenin‐positive cases that had been sequenced as part of a previous study harboured exon 3 CTNNB1 variants at VAF of 28% and 7%, respectively. Conclusion: These results demonstrate that β‐catenin alterations are relatively common in LCT, most likely occurring as subclonal events that are not enriched in cases with aggressive features. Further studies are needed to clarify the oncogenic role of β‐catenin in this tumour type. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Real-time Augmented Reality Three-dimensional Guided Robotic Radical Prostatectomy: Preliminary Experience and Evaluation of the Impact on Surgical Planning

Author

Schiavina, Riccardo, Bianchi, Lorenzo, Lodi, Simone, Cercenelli, Laura, Chessa, Francesco, Bortolani, Barbara, Gaudiano, Caterina, Casablanca, Carlo, Droghetti, Matteo, Porreca, Angelo, Romagnoli, Daniele, Golfieri, Rita, Giunchi, Francesca, Fiorentino, Michelangelo, Marcelli, Emanuela, Diciotti, Stefano, and Brunocilla, Eugenio

Published
2021
Full Text
View/download PDF

26. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Author

Dall'Olio, Filippo G., Gelsomino, Francesco, Conci, Nicole, Marcolin, Laura, De Giglio, Andrea, Grilli, Giada, Sperandi, Francesca, Fontana, Francesca, Terracciano, Mario, Fragomeno, Benedetta, Tober, Nastassja, Manferrari, Giulia, Brocchi, Stefano, Golfieri, Rita, Fiorentino, Michelangelo, and Ardizzoni, Andrea

Published
2021
Full Text
View/download PDF

27. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study

Author

Minari, Roberta, Mazzaschi, Giulia, Bordi, Paola, Gnetti, Letizia, Alberti, Giorgia, Altimari, Annalisa, Gruppioni, Elisa, Sperandi, Francesca, Parisi, Claudia, Guaitoli, Giorgia, Bettelli, Stefania, Longo, Lucia, Bertolini, Federica, Pagano, Maria, Bonelli, Candida, Tagliavini, Elena, Nicoli, Davide, Ubiali, Alessandro, Zangrandi, Adriano, Trubini, Serena, Proietto, Manuela, Fiorentino, Michelangelo, and Tiseo, Marcello

Published
2020
Full Text
View/download PDF

30. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets

Author

Caliò, Anna, Brunelli, Matteo, Segala, Diego, Pedron, Serena, Remo, Andrea, Ammendola, Serena, Munari, Enrico, Pierconti, Francesco, Mosca, Alessandra, Bollito, Enrico, Sidoni, Angelo, Fisogni, Simona, Sacco, Cosimo, Canu, Luisa, Sentinelli, Steno, Fraccon, Anna Paola, Fiorentino, Michelangelo, Scott, Cathryn, Milella, Michele, Porta, Camillo, Argani, Pedram, and Martignoni, Guido

Published
2020
Full Text
View/download PDF

32. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression 1

Author

Graff, Rebecca E, Pettersson, Andreas, Lis, Rosina T, Ahearn, Thomas U, Markt, Sarah C, Wilson, Kathryn M, Rider, Jennifer R, Fiorentino, Michelangelo, Finn, Stephen, Kenfield, Stacey A, Loda, Massimo, Giovannucci, Edward L, Rosner, Bernard, and Mucci, Lorelei A

Subjects
Urologic Diseases, Cancer, Clinical Research, Prevention, Prostate Cancer, Aging, Adult, Antineoplastic Agents, Phytogenic, Antioxidants, Carotenoids, Diet, Feeding Behavior, Humans, Lycopene, Solanum lycopersicum, Male, Middle Aged, Oncogene Proteins, Fusion, Plant Extracts, Prostatic Neoplasms, Trans-Activators, Transcriptional Regulator ERG, ERG protein expression, TMPRSS2:ERG, lycopene, prostate cancer, tomato sauce, Engineering, Medical and Health Sciences, Nutrition & Dietetics
Abstract

BackgroundThere is limited evidence that supports etiologically distinct molecular subtypes of prostate cancer, the identification of which may improve prevention. Given their antioxidant properties, we hypothesized that lycopene and tomato sauce may be especially protective against diseases harboring the common gene fusion transmembrane protease, serine 2 (TMPRSS2):v-ets avian erythroblastosis virus E26 oncogene homolog (ERG).ObjectiveWe aimed to examine associations between estimated lycopene and tomato sauce intake and the risk of prostate cancer defined by ERG protein expression subtype.DesignOur study population consisted of a prospective cohort of 46,719 men from the Health Professionals Follow-Up Study. TMPRSS2:ERG was assessed by ERG immunohistochemistry on tumor tissue microarrays constructed from radical prostatectomy specimens. We used multivariable competing risk models to calculate HRs and 95% CIs for the risk of ERG-positive and, separately, ERG-negative disease. We implemented inverse probability weighting to account for evaluating ERG status only in surgically treated cases.ResultsDuring 23 y of follow-up, 5543 men were diagnosed with prostate cancer, among whom 884 were assayed for ERG (426 ERG-positive). With inclusion of only the latter cases, increasing cumulative average tomato sauce intake was associated with a decreased risk of prostate cancer overall (≥2 servings/wk compared with

Published
2016

44. Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort.

Author

Destefanis, Nicolas, Fiano, Valentina, Milani, Lorenzo, Vasapolli, Paolo, Fiorentino, Michelangelo, Giunchi, Francesca, Lianas, Luca, Del Rio, Mauro, Frexia, Francesca, Pireddu, Luca, Molinaro, Luca, Cassoni, Paola, Giulio Papotti, Mauro, Gontero, Paolo, Calleris, Giorgio, Oderda, Marco, Ricardi, Umberto, Iorio, Giuseppe Carlo, Fariselli, Piero, and Isaevska, Elena

Subjects
PROSTATE cancer, ARTIFICIAL neural networks, DNA methylation, PROGNOSTIC models, GLEASON grading system, PROGNOSIS
Abstract

Introduction: Prostate cancer (PCa) is the most frequent tumor among men in Europe and has both indolent and aggressive forms. There are several treatment options, the choice of which depends on multiple factors. To further improve current prognostication models, we established the Turin Prostate Cancer Prognostication (TPCP) cohort, an Italian retrospective biopsy cohort of patients with PCa and long-term follow-up. This work presents this new cohort with its main characteristics and the distributions of some of its core variables, along with its potential contributions to PCa research. Methods: The TPCP cohort includes consecutive non-metastatic patients with first positive biopsy for PCa performed between 2008 and 2013 at the main hospital in Turin, Italy. The follow-up ended on December 31st 2021. The primary outcome is the occurrence of metastasis; death from PCa and overall mortality are the secondary outcomes. In addition to numerous clinical variables, the study's prognostic variables include histopathologic information assigned by a centralized uropathology review using a digital pathology software system specialized for the study of PCa, tumor DNA methylation in candidate genes, and features extracted from digitized slide images via Deep Neural Networks. Results: The cohort includes 891 patients followed-up for a median time of 10 years. During this period, 97 patients had progression to metastatic disease and 301 died; of these, 56 died from PCa. In total, 65.3% of the cohort has a Gleason score less than or equal to 3 + 4, and 44.5% has a clinical stage cT1. Consistent with previous studies, age and clinical stage at diagnosis are important prognostic factors: the crude cumulative incidence of metastatic disease during the 14-years of follow-up increases from 9.1% among patients younger than 64 to 16.2% for patients in the age group of 75-84, and from 6.1% for cT1 stage to 27.9% in cT3 stage. Discussion: This study stands to be an important resource for updating existing prognostic models for PCa on an Italian cohort. In addition, the integrated collection of multi-modal data will allow development and/or validation of new models including new histopathological, digital, and molecular markers, with the goal of better directing clinical decisions to manage patients with PCa. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome

Author

Massari, Francesco, Ciccarese, Chiara, Hes, Ondrej, Michal, Michal, Caliò, Anna, Fiorentino, Michelangelo, Giunchi, Francesca, D’Amuri, Alessandro, Sanguedolce, Francesca, Sabbatini, Roberto, Guida, Annalisa, Ardizzoni, Andrea, Porta, Camillo, Iacovelli, Roberto, Tortora, Giampaolo, Cima, Luca, Ortega, Cinzia, Lapini, Alberto, Martignoni, Guido, and Brunelli, Matteo

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results